Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
Latest Information Update: 06 Mar 2025
At a glance
- Drugs INT 301 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Acronyms OMEGA
- Sponsors Intrommune Therapeutics
Most Recent Events
- 19 Feb 2025 According to an Intrommune Therapeutics media release, results were published in the Annals of Allergy, Asthma & Immunology.
- 19 Feb 2025 Results presented in the Intrommune Therapeutics Media Release.
- 21 May 2024 According to an Intrommune Therapeutics media release, the company presented data at Citizens JMP Life Science Conference on 13th may 2024 and the BioNJ BioPartnering Conference on 14th May 2024 and the company CEO Michael Nelsonwill represent Intrommune as a panelist at the Annual Food Allergy Fund Summiton May 23rd, 2024 at 1:00pm EDT..